Skip to main content

Table 4 Association between waiting time and the change in SF-12v2 physical component scale from baseline to the 6-month follow-up, for the overall sample and by main rheumatic condition

From: The association between waiting time and multidisciplinary pain treatment outcomes in patients with rheumatic conditions

  PCS at baseline, Mean (SD) PCS at 6 months, Mean (SD) GEE models
Unadj.
p value a
Unadj. change from baseline to 6 months, EMM (95% CI) Adj.
p value a,b
Adj. change from baseline to 6 months, EMM b (95% CI)
Overall sample (n) 3210 1940 < 0.001   < 0.001  
 Total 23.5 (9.7) 26.1 (11.2)     
 < 2 months 24.3 (10.1) 28.2 (12.3)   3.8 [2.7, 4.9]   3.9 [2.7, 5.1]
 2–6 months 23.2 (9.8) 25.1 (10.6)   1.6 [0.7, 2.4]   1.6 [0.6, 2.5]
 > 6 months 23.0 (9.4) 25.3 (10.6)   1.9 [1.2, 2.6]   2.0 [1.2, 2.8]
Osteoarthritis (n) 665 395 0.009   0.057  
 Total 24.7 (9.7) 27.5 (11.2)     
 < 2 months 24.1 (9.8) 28.4 (11.4)   4.7 [2.1, 7.3]   4.3 [1.6, 7.0]
 2–6 months 24.6 (10.2) 27.0 (11.5)   1.7 [−0.4, 3.8]   1.8 [−0.6, 4.2]
 > 6 months 25.3 (9.2) 27.2 (10.7)   1.7 [0.02, 3.34]   1.9 [0.1, 3.8]
Fibromyalgia (n) 670 358 0.049   0.038  
 Total 22.7 (9.6) 25.0 (11.0)     
 < 2 months 22.7 (8.8) 26.8 (11.7)   4.4 [1.6, 7.2]   4.7 [1.6, 7.8]
 2–6 months 23.8 (10.1) 26.2 (11.3)   2.7 [0.8, 4.5]   2.3 [0.4, 4.3]
 > 6 months 21.6 (9.5) 22.9 (9.9)   1.6 [0.1, 3.1]   1.5 [−0.1, 3.1]
  1. PCS SF-12v2 Physical component scale, SD standard deviation, GEE generalized estimating equations, EMM estimated marginal means, 95% CI 95% confidence interval
  2. a Time X group effect p value
  3. b Adjusted for age, sex, pain duration, number of comorbidities and income